Generic Aggrastat Availability

Aggrastat is a brand name of tirofiban, approved by the FDA in the following formulation(s):

AGGRASTAT (tirofiban hydrochloride - injectable;injection)

  • Manufacturer: MEDICURE
    Approval date: April 20, 2000
    Strength(s): EQ 12.5MG BASE/250ML (EQ 0.05MG BASE/ML) [RLD]
  • Manufacturer: MEDICURE
    Approval date: May 17, 2002
    Strength(s): EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML)

Has a generic version of Aggrastat been approved?

No. There is currently no therapeutically equivalent version of Aggrastat available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Aggrastat. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Compositions for inhibiting platelet aggregation
    Patent 5,733,919
    Issued: March 31, 1998
    Inventor(s): Gelotte; Karl M.
    Assignee(s): Merck & Co., Inc.
    The invention is a pharmaceutical composition for intravenous administration to a patient comprising a) a pharmaceutically effective amount of a compound having the formula ##STR1## as 2-S-(n-Butylsulfonylamino)-3-›4-(4-(piperidin-4-yl)butyloxy)phenyl!propion ic acid; b) a pharmaceutically acceptable amount of a citrate buffer effective to provide a pH of between about 5 and 7; and c) a pharmaceutically acceptable amount of a tonicity adjusting agent effective to make the formulation substantially isotonic with the osmotic pressure of the biological system of the patient.
    Patent expiration dates:
    • October 23, 2016
  • Compositions for inhibiting platelet aggregation
    Patent 5,965,581
    Issued: October 12, 1999
    Inventor(s): Gelotte; Karl M.
    Assignee(s): Merck & Co., Inc.
    A composition is disclosed comprising about 0.25 mg/ml 2-S-(n-Butylsulfonylamino)-3 -›4-(4-(piperdin-4-yl)butyloxylphenyl!propionic acid, about 8 mg/ml sodium chloride, about 2.7 mg/ml sodium citrate dihydrate, about 0.16 mg/ml citric acid anhydrous, wherein the composition osmolality concentration is between about 250-310 mOsmol/kg and the pH is in the range of between 5.5-6.5.
    Patent expiration dates:
    • October 23, 2016
  • Compositions for inhibiting platelet aggregation
    Patent 5,972,967
    Issued: October 26, 1999
    Inventor(s): Gelotte; Karl M.
    Assignee(s): Merck & Co., Inc.
    The invention is a pharmaceutical composition for intravenous administration to a patient comprising a) a pharmaceutically effective amount of 2-S-(n-Butylsulfonylamino)-3-[4-(4-(piperidin-4-yl)butyloxy)phenyl]propion ic acid; b) a pharmaceutically acceptable amount of a citrate buffer effective to provide a pH of between about 5 and 7; and c) a pharmaceutically acceptable amount of a tonicity adjusting agent effective to make the formulation substantially isotonic with the osmotic pressure of the biological system of the patient.
    Patent expiration dates:
    • October 23, 2016
  • Angioplasty procedure using nonionic contrast media
    Patent 5,978,698
    Issued: November 2, 1999
    Inventor(s): Sax; Frederic L.
    Assignee(s): Merck & Co., Inc.
    A method for treating patients in need of percutaneous transluminal coronary angioplasty which comprises administering nonionic contract media to the patient and treating the patient with a fibrinogen receptor antagonist.
    Patent expiration dates:
    • October 8, 2017
  • Platelet aggregation inhibition using low molecular weight heparin in combination with a GP IIb/IIIa antagonist
    Patent 6,136,794
    Issued: October 24, 2000
    Inventor(s): Cook; Jacquelynn J. & Gould; Robert J. & Sax; Frederic L.
    Assignee(s): Merck & Co., Inc.
    A method for inhibiting platelet aggregation in a mammal comprising administering to the mammal a safe and therapeutically effective amount of a GPIIb/IIIa receptor antagonist or a pharmaceutically acceptable salt thereof and a safe and therapeutically effective amount of low molecular weight heparin. A method for inhibiting platelet aggregation in a mammal comprising administering to the mammal a safe and therapeutically effective amount of (2-S-(n-butylsulfonylamino)-3[4-(piperidin-4-yl)butyloxyphenyl]-propionic acid or a pharmaceutically acceptable salt thereof and a safe and therapeutically effective amount of low molecular weight heparin.
    Patent expiration dates:
    • January 29, 2019
  • Method for inhibiting platelet aggregation
    Patent 6,770,660
    Issued: August 3, 2004
    Inventor(s): Peter M.; DiBattiste & David; Schneider
    Assignee(s): Artery LLC
    A method for inhibiting platelet aggregation in a patient in need thereof, comprising 1) administering to the patient a bolus injection of an active drug, in an amount of about 25 &mgr;g/kg, and 2) administering to the patient, after the bolus injection, an intravenous infusion for a period of between about 12 hours and about 72 hours, of the active drug, in an amount of about 0.15 &mgr;g/kg/min, wherein the active drug is tirofiban or a salt thereof.
    Patent expiration dates:
    • May 1, 2023
    • June 1, 2023

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide
(web5)